Targeting Dendritic Cell Function during Systemic Autoimmunity to Restore Tolerance

International Journal of Molecular Sciences

Juan P. Mackern-Oberti²  Fabián Vega¹  Carolina Llanos¹  Susan M. Bueno² 

[1] Departamento de Inmunología Clínica y Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Marcoleta 350, Santiago 8330033, Chile; E-Mails:;Millennium Institute of Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Portugal 49, Santiago 8330025, Chile; E-Mails:

关键词: autoimmunity;    tolerance;    therapy;    dendritic cells;   

DOI  :  10.3390/ijms150916381

来源: mdpi

【 摘 要 】

Systemic autoimmune diseases can damage nearly every tissue or cell type of the body. Although a great deal of progress has been made in understanding the pathogenesis of autoimmune diseases, current therapies have not been improved, remain unspecific and are associated with significant side effects. Because dendritic cells (DCs) play a major role in promoting immune tolerance against self-antigens (self-Ags), current efforts are focusing at generating new therapies based on the transfer of tolerogenic DCs (tolDCs) during autoimmunity. However, the feasibility of this approach during systemic autoimmunity has yet to be evaluated. TolDCs may ameliorate autoimmunity mainly by restoring T cell tolerance and, thus, indirectly modulating autoantibody development. In vitro induction of tolDCs loaded with immunodominant self-Ags and subsequent cell transfer to patients would be a specific new therapy that will avoid systemic immunosuppression. Herein, we review recent approaches evaluating the potential of tolDCs for the treatment of systemic autoimmune disorders.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.